INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 411m ago
HOUSE PTR11m ago
SEC 13F11m ago
ROBINHOOD CHAIN10m ago
Corporate insider
SP

Soteropoulos Paula

DirectorCIK 0001692444

EDGAR filingsOpen in network
Disclosed transactions3
Buys / sells0 / 1
Max Insider Score36
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
2
SP
Soteropoulos PaulaDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$233K
27.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Dianthus Therapeutics, Inc. /DE/Director · Mar 26, 2026
36
SP
Soteropoulos PaulaDirector
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL
$2.15M
27.6K sh
Mar 24, 2026
Mar 26, 2026
traded Mar 24, 2026
+2d
SEC FORM 4

Evidence

0
SP
Soteropoulos PaulaDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
27.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence